Table 2.
Drug therapy according to the presence of CKD
| CKD+ n = 331 (17.3%) | CKD– n = 1,577 (82.7%) | p | |
|---|---|---|---|
| ASA | 324 (98.4) | 1,555 (98.7) | 0.848 |
| Clopidogrel | 325 (98.7) | 1,556 (98.8) | 0.863 |
| Glycoprotein IIb/IIIa inhibitors | 11 (3.3) | 84 (5.3) | 0.166 |
| β-Blockers | 297 (90.2) | 1,413 (89.7) | 0.861 |
| ACEI | 238 (72.3) | 1,271 (80.7) | <0.001 |
| ARB | 39 (11.8) | 190 (12.0) | 0.986 |
| Statins | 303 (92.0) | 1,480 (94.0) | 0.235 |
| Ca blockers | 122 (37.0) | 399 (25.3) | <0.001 |
| VKA | 34 (10.2) | 59 (3.7) | <0.001 |
| Prasugrel | – | 0.3 | 0.666 |
Figures are numbers, with percentages in parentheses. ASA, acetylsalicylic acid; VKA, vitamin K antagonists; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca blockers, calcium channel blockers.